- Home
- CASS vs DNTH Comparison
CASS vs DNTH Comparison
Compare CASS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASS
- DNTH
- Stock Information
- Founded
- CASS 1906
- DNTH 2015
- Country
- CASS United States
- DNTH United States
- Employees
- CASS N/A
- DNTH N/A
- Industry
- CASS Business Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- CASS Consumer Discretionary
- DNTH Health Care
- Exchange
- CASS Nasdaq
- DNTH Nasdaq
- Market Cap
- CASS 586.3M
- DNTH 565.7M
- IPO Year
- CASS 1996
- DNTH N/A
- Fundamental
- Price
- CASS $39.48
- DNTH $19.50
- Analyst Decision
- CASS Buy
- DNTH Strong Buy
- Analyst Count
- CASS 1
- DNTH 8
- Target Price
- CASS $45.00
- DNTH $54.33
- AVG Volume (30 Days)
- CASS 42.9K
- DNTH 418.5K
- Earning Date
- CASS 04-17-2025
- DNTH 05-08-2025
- Dividend Yield
- CASS 3.14%
- DNTH N/A
- EPS Growth
- CASS N/A
- DNTH N/A
- EPS
- CASS 1.53
- DNTH N/A
- Revenue
- CASS $220,944,000.00
- DNTH $6,235,000.00
- Revenue This Year
- CASS N/A
- DNTH N/A
- Revenue Next Year
- CASS $7.70
- DNTH N/A
- P/E Ratio
- CASS $26.19
- DNTH N/A
- Revenue Growth
- CASS 2.32
- DNTH 120.63
- 52 Week Low
- CASS $37.99
- DNTH $13.37
- 52 Week High
- CASS $47.14
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- CASS 38.01
- DNTH 53.31
- Support Level
- CASS $38.23
- DNTH $18.37
- Resistance Level
- CASS $40.00
- DNTH $19.76
- Average True Range (ATR)
- CASS 1.67
- DNTH 1.93
- MACD
- CASS -0.18
- DNTH 0.45
- Stochastic Oscillator
- CASS 23.19
- DNTH 95.93
About CASS Cass Information Systems Inc
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.